-
FDA sets May 2027 decision date on AMT-130 gene therapy for HD
4 min read
Latest News
-
October 2026: This Month in Huntington’s Disease Research
4 min read
From sticky thoughts and pigs that model HD to DNA repair and promising drug trial results, October brought fresh insights into HD. Here’s what you might have missed!
-
Huntington's disease therapeutics conference 2019 – Day 2
5 min read
New tools to bridge the gap between the lab and patients in our update from day 2 of the 2019 HD Therapeutics conference
-
Huntington's disease therapeutics conference 2019 – Day 1
9 min read
HDBuzz reports from the annual Huntington’s disease therapeutics conference in Palm Springs
-
Huntington's disease goes viral as UniQure inches ahead in gene therapy race
9 min read
FDA grants “Investigational New Drug” status to Huntingtin-lowering gene-therapy agent AMT-130, clearing path to human trials in Huntington’s Disease patients
-
Advances on many fronts in the battle against the protein that causes Huntington's disease
11 min read
This fall sees exciting announcements from a number of companies focused on novel Huntingtin Lowering technologies, including Wave, PTC and Voyager
-
HDSA FAQ on the Roche/Genentech RG6042 program
18 min read
HDSA's frequently asked questions factsheet about the huntingtin-lowering trial ASO program was so good we stole it (with permission)
-
Kids sometimes get Huntington’s disease too
6 min read
Finally, a big study that shows what childhood HD looks like. This will help us work out if new drugs work in children too
-
Roche announces details of its 'pivotal' huntingtin-lowering study
10 min read
The GENERATION-HD1 trial will test whether RG6042 – formerly Ionis-HTTRx – slows the progression of Huntington's disease
-
Disappointing news from LEGATO-HD trial of laquinimod in Huntington's disease
5 min read
The LEGATO-HD trial of laquinimod did not slow progression of Huntington's disease. Here's the lowdown.
-
HDBuzz Enrolls in Enroll-HD
12 min read
As promised, HDBuzz's Jeff Carroll finally signed up for the Enroll-HD study. Learn more about this important global HD "observational study" here.
-
First Dolly, now Piglet; a new Huntington’s disease pig knock-in model confirmed
7 min read
For the first time in HD research, an animal model has been created in pigs using 2 cutting edge DNA editing t
HDBuzz Trial Tracker
FDA accepts BLA for Priority Review, with a target decision date of 1 May 2027.
Show 8 more Show less
Updates from the ongoing Phase 3 INVEST-HD trial of votoplam
Updates from the Phase 1b/2a REGEN4HD trial of neural stem cell therapy hNSC-01
Updates from the ongoing Phase 2/3 FALCON-HD trial of SKY-0515
